Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sequoia, HBM Bioventures Invest In Nuokang Bio-Pharmaceutical

This article was originally published in PharmAsia News

Executive Summary

Sequoia Capital China and HBM Bioventures will be injecting $17 million into Nuokang Bio-Pharmaceutical, a subsidiary of Nuokang Medicine, to secure 20 percent of the drug manufacturer's shares. Both venture capitalists will likely increase their investment if the biologics firm intends to expand by acquisitions in the future. Besides financials, the two will also bring their experience in resource and capital market management to help the Chinese company develop a global strategy. Nuokang Bio-Pharmaceutical, based in Shenyang, Liaoning province, is launching two new drugs this year and will use the funds for market development, distribution network establishment, and other projects. Its new international-standard production base is currently under construction. (Click here for more - Chinese Language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC067813

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel